IBB Is Positioned For Outperformance

iShares Nasdaq Biotechnology ETF is benefitting from reduced regulatory risk in the middle term. The ETF is still trading below its highs of 2015, so it has a lot of ground to recover going forward.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.